Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

8.510 -0.500 (-5.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,878,101
Open 8.760
Bid (Size) 8.520 (2)
Ask (Size) 8.590 (9)
Prev. Close 9.010
Today's Range 8.420 - 8.935
52wk Range 4.970 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. 
Via The Motley Fool
Nvidia’s Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance
These Nvidia partner stocks stand to gain from the semiconductor's industry dominance, but they have plenty of upside of their own. 
Via InvestorPlace

Performance

YTD
-13.78%
-13.78%
1 Month
-1.50%
-1.50%
3 Month
-17.94%
-17.94%
6 Month
+12.57%
+12.57%
1 Year
-8.49%
-8.49%

More News

Read More
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Owns These 2 AI Stocks. Should You?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
Recursion Pharm Stock Sees Relative Strength Rating Rise To 84
Via Investor's Business Daily
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
Via The Motley Fool
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Via The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Stocks That Could 10x by 2035
Via The Motley Fool
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
Via Benzinga
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
Via The Motley Fool
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
The Next Drug You Take May be Designed By A.I.
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Is Buying This Under-the-Radar AI Stock
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.